Is IBRX a buy or a sell?
The Discounted Cash Flow (DCF) valuation of Immunitybio Inc (IBRX) is (50.51) USD. With the latest stock price at 2.74 USD, the upside of Immunitybio Inc based on DCF is -1943.6%. This means that IBRX is a sell according to the DCF valuation model.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 7.1% - 8.8% | 7.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (91.76) - (35.78) | (50.51) |
| Upside | -3448.9% - -1405.9% | -1943.6% |